304 completed. 304 Phase 3, 32 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 304 | Completed 304 |
| Phase 2 | 32 | Completed 32 |
Follow Prostatic Neoplasms: new trials by email Literature Review of Prostatic Neoplasms trials Research Report on Prostatic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer QLG1080 - Prostate Cancer | Phase 3 | Completed | Qilu Pharmaceutical Co., Ltd. | 111 | 2025-03-11 | 2026-09-03 |
| Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer Florastamin[18F] Injection - Prostate Cancer | Phase 3 | Completed | HTA Co., Ltd. | 131 | 2024-12-19 | 2026-09-25 |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer Copper Cu 64 PSMA I&T - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Completed | Curium US LLC | 235 | 2024-04-01 | 2026-02-18 |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer Copper Cu 64 PSMA I&T - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Completed | Curium US LLC | 443 | 2024-04-01 | 2026-11-19 |
| Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer [18F]Florastamin Injection - Prostate Cancer | Phase 3 | Completed | HTA Co., Ltd. | 287 | 2023-10-20 | 2026-09-29 |
| Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate Relugolix, Leuprolide Acetate - Prostate Cancer | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 387 | 2023-01-28 | 2026-06-15 |
| Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate Triptorelin pamoate (embonate) salt - Advanced Prostate Cancer, Metastatic Prostate Cancer | Phase 3 | Completed | Ipsen | 195 | 2022-11-17 | 2025-09-09 |
| Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate Triptorelin embonate 22.5 mg - Prostate Cancer | Phase 3 | Completed | Ipsen | 147 | 2022-08-30 | 2025-07-25 |
| 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Completed | Mayo Clinic | 163 | 2022-05-09 | 2025-07-18 |
| Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP) PSMA PET guided prostate biopsy, MRI directed TRUS guided prostate biopsy - Prostate Cancer, Prostate Neoplasm | Phase 2 / Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 217 | 2021-10-25 | 2025-08-07 |
| Study of Diagnostic Performance of [18F]CTT1057 in BCR [18F]CTT1057, [68Ga]Ga-PSMA-11 - Prostatic Neoplasms, Prostate Cancer | Phase 3 | Completed | Novartis Pharmaceuticals | 190 | 2021-09-30 | 2025-10-20 |
| 68Ga-PSMA-11 PET in Patients With Prostate Cancer Ga-PSMA-11 - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Completed | University of Colorado, Denver | 39 | 2021-09-29 | 2023-11-13 |
| Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection [18F]CTT1057 - Prostatic Neoplasms, Prostate Cancer | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 195 | 2021-09-07 | 2025-10-07 |
| Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer [18F]PSMA-1007 - Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Completed | ABX advanced biochemical compounds GmbH | 136 | 2021-08-27 | 2025-07-15 |
| Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy Sugammadex 6 mg/kg, Sugammadex 4 mg/kg - Prostate Cancer, Neuromuscular Blockade | Phase 3 | Completed | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 34 | 2021-07-13 | 2023-01-25 |
| 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT - Prostatic Neoplasms | Phase 3 | Completed | Novartis Pharmaceuticals | 469 | 2021-06-15 | 2026-11-04 |
| TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer TAVT-45, Zytiga, Prednisone - Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | Phase 3 | Completed | Tavanta Therapeutics | 107 | 2021-05-05 | 2024-01-16 |
| Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT Sodium Fluoride F-18 Injection, Technetium[99mTc] Methylenediphosphonate Injection - Bone Metastases | Phase 3 | Completed | HTA Co., Ltd. | 280 | 2021-03-29 | 2022-11-14 |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib Rucaparib - Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer | Phase 3 | Completed | pharmaand GmbH | 34 | 2021-03-22 | 2024-05-07 |
| Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer Darolutamide (Nubeqa, BAY1841788), Placebo, Androgen deprivation therapy (ADT) - Prostatic Neoplasms | Phase 3 | Completed | Bayer | 669 | 2021-02-23 | 2026-09-29 |
Showing 20 of 304. Sign in to see all of them.
Neoplasms (21) · Neoplasm Metastasis (16) · Breast Neoplasms (14) · Pain (10) · Osteoporosis (6) · Carcinoma, Non-Small-Cell Lung (5) · Disease (5) · Lung Neoplasms (5) · Colonic Neoplasms (4) · Multiple Myeloma (4) · Ovarian Neoplasms (4) · Prostatic Neoplasms, Castration-Resistant (4) · Rectal Neoplasms (4) · Uterine Cervical Neoplasms (4)
Genital Diseases (304) · Urogenital Diseases (304) · Genital Diseases, Male (302) · Male Urogenital Diseases (302) · Neoplasms by Site (302) · Prostatic Diseases (302) · Urogenital Neoplasms (302) · Genital Neoplasms, Male (301) · Neoplasms (283) · Pathological Conditions, Signs and Symptoms (40) · Pathologic Processes (27) · Neoplastic Processes (17) · Signs and Symptoms (17) · Breast Diseases (14) · Skin Diseases (14)
Prednisone (35) · bicalutamide (30) · Goserelin (29) · Radiotherapy (29) · Leuprolide (25) · Docetaxel (22) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (20) · Flutamide (18) · Triptorelin Pamoate (11) · Zoledronic Acid (11) · Gonadotropin-Releasing Hormone (10) · gallium 68 PSMA-11 (10) · Androgen Antagonists (9) · Abiraterone Acetate (8) · Mitoxantrone (7)
Radiation Therapy Oncology Group (18) · Ferring Pharmaceuticals (17) · Alliance for Clinical Trials in Oncology (11) · AstraZeneca (7) · Novartis Pharmaceuticals (7) · SWOG Cancer Research Network (7) · Sanofi (7) · UNICANCER (7) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Abbott (5) · Amgen (5) · National Cancer Institute (NCI) (5) · Pfizer (5) · Bayer (4) · Blue Earth Diagnostics (4)
United States (162) · Canada (93) · France (72) · United Kingdom (63) · Netherlands (56) · Germany (55) · Belgium (53) · Italy (51) · Spain (51) · Poland (43) · Australia (41) · Russia (41) · Czechia (34) · Sweden (33) · Hungary (31)
Eric J. Small, MD (4) · Michel Bolla, MD (4) · Thomas Hope, MD (4) · George Wilding, MD (3)
PMID 34350976, PMID 24722180, PMID 29272162, PMID 38320143, PMID 25592642, PMID 36884035, PMID 22129214, PMID 33270906, PMID 35643841, PMID 35731340, PMID 36596347, PMID 21917607, PMID 23228299, PMID 24957547, PMID 25712310, PMID 25829400, PMID 26031410, PMID 26278649, PMID 26609008, PMID 29500065, PMID 30920593, PMID 31830211, PMID 32808077, PMID 33740734, PMID 33999161, PMID 34518652, PMID 35812443, PMID 37121865, PMID 37751207, PMID 42286315, PMID 10604271, PMID 10717606, PMID 10866876, PMID 10869758, PMID 11289126, PMID 11448906, PMID 11586207, PMID 11828353, PMID 12126818, PMID 12160582, PMID 12177096, PMID 12208577, PMID 12560440, PMID 12743142, PMID 12947070, PMID 14572748, PMID 14581419, PMID 14747052, PMID 15020604, PMID 15169799
2008 (7), U10CA031946 (5), 2009 (4), 2018 (4), U10CA032102 (3), 2016 (2), 2017 (2), U10CA037429 (2), 2005 (1), 2015 (1), 2019 (1), 2023 (1), P30CA006927 (1), P30CA008748 (1), P30CA014236 (1)